Nabriva Therapeutics plc (NBRVF)
Nabriva Therapeutics plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Dublin, DU, IE. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $323. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -160.3%. Its beta of -0.68 implies it has historically moved less than the broad market.
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics plc is most often compared with the following Healthcare names: